Passage BIO, Inc. (PASG) stock
PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.25+0.24 (+5.99%)
Close on Nov 13, 2026Market cap $13.68MP/E –Yield –
Passage BIO enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Passage BIO's enterprise value was -$11.28M on Nov 11, 2026, against -$24.70M a year earlier. Over the last 5 years it ranged from -$207.28M to -$2.60M, with a median of -$48.28M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$11.28M | – |
| 2025 | Dec 31, 2025 | -$15.26M | – |
| 2024 | Dec 31, 2024 | -$48.90M | – |
| 2023 | Dec 29, 2023 | -$76.00M | – |
| 2022 | Dec 30, 2022 | -$136.55M | – |
| 2021 | Dec 31, 2021 | -$2.60M | -100.3% |
| 2020 | Dec 31, 2020 | $858.48M | – |
See a number that looks wrong?